Home » FDA Clears Bot Image’s AI Software for Prostate Cancer Screening
FDA Clears Bot Image’s AI Software for Prostate Cancer Screening
The FDA has granted clearance to Bot Image’s ProstatID AI software for analysis of non-contrast “short form” magnetic resonance imaging (MRI) scans to screen for prostate cancer.
The AI software eliminates the use of MRI contrast dye that uses gadolinium, a known toxic metal, that can potentially build up in the brain and kidneys with possible side effects.
Eliminating the contrast dye from prostate cancer MRIs enables more frequent, low-cost scans for active surveillance, the company said.
Clinical studies showed that the ProstatID algorithm has an accuracy of 93.6 percent for detection of prostate cancer.
Related Topics
Upcoming Events
-
21Mar
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr